NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prevenar13 Drug Use Investigation - Adults Aged 65 Years or Older-

CompletedN/A

Sponsor: Pfizer

Conditions: Adult Not Younger Than 65 Years

Countries: Japan

This study aims to understand the following items in post-marketing actual clinical settings to evaluate the safety of 13vPnC administered as a single dose in the elderly (adults aged 65 years or older). 1. To confirm the use in actual clinical settings 2. To confirm the occurrence of adverse events

Eligibility overview

Sex: ALL

Age: 65 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Geriatric patients vaccinated with this product (adult not younger than 65 years)
2. Consent of vaccine recipients \[Vaccine recipient (or his/her legally acceptable representative) must sign and date the consent form warranting that the relevant information concerning this Study was appropriately communicated to the recipient\].

Exclusion Criteria:

None

Locations (1)

Tokyo, Japan